Note: Ingredients listed on restricted chemical lists
EC/CAS
77-92-9
Name of the chemical
Citric acid
Concentration
N/A
EC/CAS
9003-11-6
Name of the chemical
poly(ethylene propylene) glycol
Concentration
N/A
EC/CAS
532-32-1
Name of the chemical
Benzoic acid and its sodium salt
Concentration
N/A
EC/CAS
57-50-1
Name of the chemical
Sucrose, pure C12H22O11
Concentration
N/A
General Information
Version
00
Revision date
2015-12-03
Product name
Megestrol Acetate Oral Suspension USP
Product Synonyms
Compare to Megace®
1.2.1 Relevant identified uses
Pharmaceutical product indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome
Emergency telephone
800.424.9300
Icons in SDS
Company Information
company name
Pharmaceutical Associates, Inc
Section 2
SECTION 2: Hazards identification
OSHA Hazards Classification This product is a mixture and is a pharmaceutical product. It is considered non-
Precautionary statements
General advice: Seek medical attention in case of accidental exposure or overdose. Eyes: Avoid contact with eyes. Skin Contact: Avoid skin contact. Inhalation: Not intended for inhalation. Ingestion: Generally safe at recommended doses. In case of overdose, seek medical attention immediately.
Storage
There are no special storage conditions for safety. For product integrity, store under conditions specified on the label.
Disposal
Dispose of in accordance with applicable laws and regulations.
2.1 Classification of the substance or mixture
This product is a mixture and is a pharmaceutical product. It is considered non- Hazardous according to the OSHA Hazard Communication Standard 2012 (29 CFR 1910.1200). Chemical family: Mixture Statement of Hazard: Product is generally safe when used as recommended. Additional Hazard Information: Short term: Women of child bearing potential should be advised to avoid becoming pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant, the patient should be apprised of the potential hazard to the fetus. Long term: Based on a two year study in rats, long term treatment with megestrol acetate may increase the risk of respiratory infections, decreased lymphocyte counts and increased neutrophil counts. Known Clinical Effects: Adverse reactions may include nausea, vomiting, hypertension, thromboembolic phenomena, and edema. EU Indication of danger: Not classified. 00 Emergency overview Seek medical attention in case of accidental exposure or overdose. The product is generally safe when used as prescribed. Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential of exposure in your workplace.
